Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02056899 · ClinicalTrials.gov registry record · Phase 1

Maintenance Gabapentin to Prolong Pregnancy.

A Phase 1 study, sponsored by State University of New York at Buffalo.

Completed
Registry status
Phase 1
Development phase
4
Enrollment target

NCT02056899 is a Phase 1 study that has completed, run by State University of New York at Buffalo. The registered enrollment target is 4 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02056899, a Phase 1 study, has completed, sponsored by State University of New York at Buffalo.

COMPLETED
Registry status
Phase 1
Development phase
4 participants
Enrollment target

Study Summary

This is a pilot study to evaluate the tolerability and effects of maintenance gabapentin therapy on the rate of premature birth in women who have had preterm labor.

Interventions

  • DRUG Gabapentin

Trial Details

FieldValue
Enrollment Target 4 participants
Start Date 2013-06
Est. Completion 2015-08
Phase Phase 1

What the Registry Record Tells You About NCT02056899

The ClinicalTrials.gov registry entry for NCT02056899 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is State University of New York at Buffalo, which has 243 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Gabapentin is the first listed.

NCT02056899 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02056899 about?

NCT02056899 is a clinical study titled "Maintenance Gabapentin to Prolong Pregnancy.". This is a pilot study to evaluate the tolerability and effects of maintenance gabapentin therapy on the rate of premature birth in women who have had preterm labor.

What is the current status of trial NCT02056899?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2013-06. Estimated completion is 2015-08.

What interventions are being tested in trial NCT02056899?

The interventions under investigation include: Gabapentin (DRUG).

Who is sponsoring clinical trial NCT02056899?

This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.